Jupiter Neurosciences, INC

Jupiter Neurosciences, Inc. disclosed the issuance and sale of 11,470,000 shares of Common Stock to YA II PN, Ltd. for approximately $3.6 million.

Jupiter Neurosciences, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors, ratification of auditors, and approval of equity plan and reverse stock split amendments.

Jupiter Neurosciences has secured an exclusive U.S. license for PharmAla's ALA-002, a psychedelic compound for neuroinflammation, involving significant upfront and milestone payments.

Jupiter Neurosciences, Inc. announced the appointment of Dr. Tomas J. Philipson, a health care economist, to its Board of Directors, effective June 26, 2026.

Jupiter Neurosciences, Inc. has updated executive employment terms and issued stock option grants to key leadership and directors.

Jupiter Neurosciences announced the pricing of a registered direct offering expected to raise approximately $2.0 million.

Jupiter Neurosciences reported a wider net loss for Q1 2026, driven by increased general and administrative expenses, while R&D costs decreased.

Jupiter Neurosciences reports significant losses and negative cash flow, raising substantial doubt about its ability to continue as a going concern, despite strategic product development and new financing efforts.

Jupiter Neurosciences reported a significantly widened net loss in Q2 2025, driven by increased R&D and G&A expenses, while advancing its JOTROL clinical program and Nugevia supplement launch.

Jupiter Neurosciences reports its Q1 2025 financial results, focusing on research and development, particularly for its Parkinson's disease program.

Jupiter Neurosciences, a clinical-stage pharmaceutical company, released its Q3 2024 results, detailing financial performance, strategic agreements in Asia, and the closing of its initial public offering.

Jupiter Neurosciences, a clinical-stage pharmaceutical company, reported significant net losses and negative cash flows for 2025, raising substantial doubt about its ability to continue as a going concern, despite launching a new consumer product line and advancing clinical trials.

Jupiter Neurosciences' 10-K filing details its capital structure and strategic focus on developing JOTROL, a resveratrol formulation, for neuro-inflammatory conditions like Parkinson's and Alzheimer's.

Julie B. Kampf, a Director of Jupiter Neurosciences, Inc., reported multiple transactions in common stock on June 2, 2025.

Alexander Gustaf Erik Rosen, Chief Administrative Officer of Jupiter Neurosciences, Inc., reported multiple transactions in common stock on June 2, 2025.

Marshall A. Hayward, Chief Scientific Officer and a Director of Jupiter Neurosciences, Inc., reported multiple transactions in common stock on June 2, 2025.

Nicholas H. Hemmerly, a Director of Jupiter Neurosciences, Inc., reported multiple transactions in common stock on June 2, 2025.

Holger Weis, a Director of Jupiter Neurosciences, Inc., reported multiple transactions in common stock on June 2, 2025.

Jupiter Neurosciences, Inc. reports a grant of stock options to Director Tomas Jan Philipson, with a portion tied to his board appointment and the remainder in lieu of cash compensation.

Jupiter Neurosciences, Inc. filed a supplement to its definitive proxy statement to correct scriveners' errors regarding the maximum number of shares issuable under its Standby Equity Purchase Agreement and Convertible Notes.

Jupiter Neurosciences, Inc. has filed a definitive proxy statement with the SEC.

Jupiter Neurosciences, Inc. is seeking stockholder approval for a significant increase in authorized common stock and a $20 million equity purchase agreement to fund its operations and clinical trials.

Jupiter Neurosciences, Inc. has filed a registration statement for the resale of up to 16,000,000 shares of common stock by YA II PN, LTD (Yorkville) pursuant to an existing Standby Equity Purchase Agreement.

Jupiter Neurosciences, a clinical-stage pharmaceutical company, has entered a $20 million standby equity purchase agreement with Yorkville to fund its Parkinson's trial and Nugevia brand launch, despite significant and increasing net losses and a going concern warning.

Jupiter Neurosciences files an amendment to its Form S-1 registration statement to include the consent of Assurance Dimensions and update the exhibit index.

Jupiter Neurosciences amends its S-1 registration statement, highlighting its focus on Parkinson's disease treatment with JOTROL and potential expansion in the South-East Asian market.

Jupiter Neurosciences aims to raise capital through an IPO to fund the development of its Parkinson's drug, JOTROL, and expand its business operations in Southeast Asia.

Jupiter Neurosciences is seeking to raise capital through an IPO to advance its JOTROL drug, particularly for Parkinson's disease, and expand into the South-East Asian market.